cancer Archives - Missourinet

Bipartisan Missouri legislative effort to restore cuts to Mizzou’s NextGen Precision Health initiative

May 4, 2020 By Brian Hauswirth

While the budget approved last week by the Missouri House cuts funding for the state’s public colleges and universities, lawmakers on both sides of the aisle hope some of those cuts can be restored this summer. And two key lawmakers from different parties are calling on the Senate to restore funding for the UM System’s top priority, which is a major health initiative.

The $34.9 billion state operating budget approved by the House on Wednesday includes cuts to the state’s public colleges and universities. House Budget Committee Chairman Cody Smith, R-Carthage, addressed the issue on the floor on Wednesday, telling colleagues that all public two and four-year schools would receive a ten percent reduction over what was appropriated last year, under the budget.

Missouri House Budget Committee Chairman Cody Smith, R-Carthage, speaks about the budget on the House floor in Jefferson City on April 29, 2020 (photo courtesy of Tim Bommel at House Communications)

“I realize that this causes consternation across the General Assembly, and it’s not an easy thing to do,” Smith says. “But again we’re looking at a tremendously difficult budgetary outlook year.”

Chairman Smith says it’s possible that state lawmakers will be called back for a special session this summer, and says that if additional federal funding comes down, he’d like to see the money restored.

“It will be a conversation that we will need to talk about at that time, if we have some additional federal money to spend, or if we are able to reallocate some general revenue,” says Smith.

The Carthage Republican says the House may be called to return to Jefferson City this summer, for supplemental budgets.

Meantime, State Reps. Sara Walsh, R-Ashland, and Greg Razer, D-Kansas City, are calling on the Senate to restore about $700,000 in cuts to Mizzou’s NextGen Precision Health initiative. The NextGen Precision Health Institute, which is under construction, is expected to train the next generation of scientists who will help Missouri address future health care needs.

The $220 million facility is the UM System’s top capital priority. Mizzou says researchers in areas like medicine and engineering will work in the institute, to advance lifesaving research.

Representative Razer, a Mizzou graduate who is the ranking Democrat on the House Higher Education Committee, announced on the floor Wednesday that someone in his immediate family has just been diagnosed with cancer.

Razer predicts the facility will accelerate medical breakthroughs.

“This is truly a space that can cure cancer. They have the capability of curing cancer at the University of Missouri,” Razer says.

Razer tells the House that the UM System requested $10 million from the state. Governor Mike Parson’s budget recommendation reduced that to $3 million, and as of now, lawmakers have it at $0. Razer wants to see the Senate restore some funding.

Representative Walsh, who chairs the House appropriations subcommittee on transportation, is also a Mizzou graduate. She spoke on the floor after Razer, proposing using $729,000 originally intended for Fort Leonard Wood’s airport. She notes that money will lapse and won’t be needed at Fort Leonard Wood for another year.

“And that is money that I believe is a good purpose for it to be put to use for the precision medicine initiative,” says Walsh, whose district includes part of Columbia.

Walsh announced on the floor that she is working with Senate Majority Leader Caleb Rowden, R-Columbia, to partially restore some of the cuts to the NextGen Precision Health initiative and to Boone County Task Force One, which is a Columbia-based search-and-rescue team. She says she supports utilizing state revenues most effectively, to help ease the pain being felt now.

Mizzou says the institute will play a key role in the NextGen Precision Health Initiative, which supports the research activities of the UM System’s four campuses and health system.

University leaders broke ground on the institute last June.

“The NextGen Precision Health Initiative will help bring us bring laboratory research to effective treatments, which will benefit all Missourians as well as the rest of the world,” UM System President Dr. Mun Choi said at the 2019 groundbreaking ceremony.

The institute is being funded through a combination of private and corporate support, state support and contributions from Mizzou and the UM System.

Scientists find mutated genes related to 12 cancer types

October 17, 2013 By Mike Lear

Scientists at the Washington University School of Medicine looking at 12 different types of cancer have identified 127 significantly mutated genes that appear to drive development of a range of tumors in the body. Those scientists hope the findings and more like them in the future could become part of standard cancer diagnosis.

Li Ding, PhD of the Genome Institute at Washington University

Doctor Li Ding says the ability to identify those genes combined with additional research in the future could lead to a complete list of cancer genes responsible for all human cancers.

“Once we identify the specific mutation … we know which string the mutation is from … we can use existing drugs or develop novel therapy for treating the cancer.”

She says doctors can begin using the results found so far, while further research will look at more tumor samples and more cancers to look for more mutated genes.

“I believe that by increasing the sample size and increasing the tumor types we should be able to identify almost all the important cancer genes responsible for the development of different types of human cancers in the near future.”

A cancer gene panel set could be used upon diagnosis or after a patient has already been diagnosed.

Ding believes more important is that it could be used for cancer prognosis, making it another step toward more effective and individualized treatments. “Knowing after a patient has been diagnosed with cancer, then we can look at the specific mutations they have and develop a targeted therapy.”

The research utilizes advances that make analysis of cancer cells faster and cheaper.

Findings suggest tailored approach better at treating cervical tumors

June 5, 2013 By Mike Lear

Doctors at Washington University in St. Louis say they’ve learned that preliminary testing on cervical tumors can predict how effective standard treatments will be on them.

A PET/CT scan reveals a cervical tumor in the left image that is no longer visible after successful treatment, in the right image. (image courtesy; Washington University)

Assistant professor of radiation oncology Julie Schwarz, MD, PhD, says the current treatment of cervical cancer beyond a certain stage employs platinum.

“Platinum is thought to be a radiosensitizer so it’s thought that just getting this a spot in chemotherapy helps the radiation work better, but one of the findings from this study is that the individual tumor cell’s sensitivity to that reagent, if it doesn’t respond to that reagent, it doesn’t do well. That sort of tells us that the chemotherapy by itself and picking the right chemotherapy is really, really important.”

Schwarz says this study was limited in scope, though, and she hopes it will lead to a case study that might help develop a more definitive test.

“You would enroll patients on a study where you would test their tumors up front to figure out if they’re insensitive to platinum. If they were insensitive to platinum would you then pick another reagent, and the question is what reagent would you pick, first of all, and how would you sort of rationalize and put patients in groups, and that’s sort of where some of our laboratory work is coming into play.”

Schwarz says researchers at Washington University are looking at how a number of cancers are treated and asking the same kinds of questions.

“This research is just part of a whole group of studies that’s being performed to figure out if [using standard treatments] is the right approach, and the results of this study and many others are sort of leading us to believe that’s not the right assumption … that we need to sort of individualize chemotherapy treatment for cervical cancer.”

She thinks that even in the next decade, doctors might be able to use a preliminary test on certain types of cancers to determine what treatments will be most effective on an individual tumor. Her aim is to make sure that cervical cancer is one of them.

The new findings have been published in the online journal Gynecologic Oncology.

Professor: cancer breakthrough ‘close to putting a man on the moon’ (AUDIO)

September 23, 2012 By Mike Lear

Research done largely in St. Louis has uncovered a link between two types of cancer that could lead to better treatment of one, and eventually others.

A comprehensive analysis of basal-like breast cancer cells like these showed they are genetically more like ovarian tumors than other breast cancers. The findings could lead to more effective treatment of that form of breast cancer using drugs previously used on such ovarian tumors.

Scientists have known that breast cancer is not one disease, but the analysis is shedding light on the nature of differences between its forms. The findings join other evidence for the concept of cataloging tumors and treating them based on genetic disruptions rather than where they are found in the body.

Study co-leader Matthew Ellis, MD, PhD is a Professor of Medicine at the Siteman Cancer Center at Washington University. He says the work will prove to be very significant.

“We’ve never been able to do this before. This really is a breakthrough in cancer research that’s close to putting a man on the moon.”

Ellis says striking similarities were found between the genetic profiles of one of the most deadly types of breast cancer and an aggressive form of ovarian cancer. “These two tumors are close cousins genetically, which is very interesting because in fact we treat ovarian cancer and breast cancer of this type with different drugs. It leads to the hypothesis that perhaps we could learn a lot from the way we treat ovarian cancer in terms of how we treat this form of breast cancer that occurs in about 15 percent of our patients.”

The findings involve basal-like breast tumors that account for 10 percent of all breast cancers and disproportionately affect younger women and those who are African-American.

Read more on the findings in the journal Nature.

Ellis says the result could be treatments that are tailored more precisely and effectively to each form of breast cancer.

“There’s one drug we use in breast cancer that we don’t use in ovarian cancer called an anthracycline. This drug is actually a difficult drug to use from the patient’s perspective because it’s quite toxic, and on top of that it may cause heart damage and leukemia. So if our relationship with ovarian cancer is true, then maybe we don’t actually need to use this drug to treat this particular form of breast cancer.”

He continues, “On the ovarian cancer side there’s a couple of drugs … one approved and one in development … which are not routinely used in the treatment of breast cancers but perhaps should be for the type of breast cancer that looks like ovarian cancer. One’s called a ‘platinum agent,’ and the one in development is called a “PARP inhibitor.’

“This sort of look across cancers has led to some very interesting hypotheses that could increase the cure rate, and perhaps also … the safety of the chemotherapy administration.”

Study co-leader Matthew J. Ellis, MD, PhD is the Anheuser-Busch Chair in Medical Oncology at Washington University School of Medicine in St. Louis.

Ellis says using genome research information will allow for a sort of “designer research,” and that is where improvements in treatment will come from. “Instead of giving a sort of ‘one size fits all’ three drug combination, which is what’s been done for years, you really focus on the fact that these are different diseases and different biologies, and to address individual hypotheses that really stem from understanding where these diseases are coming from, massive improvements will be seen.

“I don’t think this is going to be a small advance. I think this is going to be quite a significant advance in many instances.”

One of the next steps will be to put the findings in the hands of doctors, but not without some instruction to help them understand and utilize it. “We want to have a very rigorous research plan supported in part by the National Institutes of Health and in part by the pharmaceutical industry to come up with a much more structured, logical and in all likelihood, highly effective approach to improving breast cancer outcomes.”

He stresses the findings are meaningful for more than patients with basal-like tumors. “There’s hope for all patients with breast cancer, but that hope stems from different understandings of these different subtypes, so it won’t be a single solution for all patients, but individualized solutions.”

The effort is part of The Cancer Genome Atlas project, involving leading genetic sequencing centers including The Genome Institute at Washington University. Ellis says a “huge amount” of the work is happening in St. Louis. The other co-leader is Charles M. Perou, PhD at the University of North Carolina.

AUDIO: Mike Lear interviews Matthew Ellis, MD, PhD, 12:53